Loading
Jade Biosciences, Inc. Stock: price and insider trades · United States
US·Mcap US$1.3B
No insider purchase over the last 90 days. The latest was filed 19 May 2025.
Jade Biosciences, Inc.: what insiders have been doing
Every trade that managers of Jade Biosciences, Inc. disclose to SEC (Form 4) is tracked on this page. The last twelve months, up to 18 October 2026, brought 4 filings signed by 4 insiders.
None of the filings is a plain purchase or sale on the open market; they cover grants, option exercises and other movements. Such operations are usually part of compensation schedules, which makes them a weaker signal than an open-market trade.
For context, the typical company on the same exchange (median of 5,458 companies) published 22 filings over the same period, against 4 filings here. Looking back to 2021, when coverage begins, insiders filed 2 purchases and 28 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists net income at -127.4 m USD.
Over the last twelve months, not one insider purchase of Jade Biosciences, Inc. stock was filed. Filings reach the SEC (Form 4) feed a median of 1 day after the trade. Section 16 rules allow two business days to file each Form 4.
In the same market, recent insider purchases at GameStop Corp. and Heico Corp also feature in our signals. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
142
Thresholds
n/a
Buy Volume
€1M
2 ops. · all time
Sell Volume
€2M
28 ops. · all time
Who traded when
BuySaleTom Frohlich1 buy
Since the insiders bought
- +202.5%Entry US$7.72 · Close at T+365 US$23.34
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Jade Biosciences, Inc. Strong Buy (bullish), based on 8 analysts. Average price target: US$48.50.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2025FY ended December 2025 · cache
US$21.72
Analyst consensus
8 analystsStrong buy
US$40.00Target US$48.50(+123%)US$74.00
Income statement
EBITDA-US$113.5M
Net income-US$127.4M0.0% margin
Valuation
PER (forward)-9.5x
P/Book3.6x
Balance sheet & cash
Market capUS$1.3B
Total debtUS$724k
Free Cash Flow-US$94.9M
Debt / Equity0%
Profitability & ownership
% insiders0.8%
% institutions104.2%
Last declaration on 13 February 2026
Declarations142 total
28,125 shares0Common StockSEC:0001193125-26-052055:0
78,750 shares0Common StockSEC:0001193125-26-052054:0
41,250 shares0Common StockSEC:0001193125-26-052053:0
37,813 shares0Common StockSEC:0001193125-26-052056:0
1,333,126 shares@ US$9.14100.0% of flowCommon StockSEC:0001104659-25-097921:0
6,000 shares@ US$7.40100.0% of flowCommon StockSEC:0000950170-25-074496:0
Canonical exit: 14 Aug 2025 (T+90)
1,062,326 sharesCommon StockSEC:0001415889-25-011583:0
11,454 shares@ US$1.741.5% of flowCommon StockSEC:0001415889-24-020662:0
928,110 shares@ US$1.67100.0% of flowCommon StockSEC:0001415889-24-017703:0
Canonical exit: 15 Sept 2024 (T+90)
6,000 shares@ US$2.147.0% of flowCommon StockSEC:0001415889-24-016993:0
15,000 shares@ US$2.145.2% of flowCommon StockSEC:0001415889-24-016995:0
10,600 shares@ US$14.5938.8% of flowCommon StockSEC:0001415889-24-016994:0
10,000 shares@ US$2.144.7% of flowCommon StockSEC:0001415889-24-013629:0
4,000 shares@ US$2.144.6% of flowCommon StockSEC:0001415889-24-013630:0
1,981 shares@ US$21.01510.4% of flowCommon StockSEC:0001415889-24-012235:0
10,000 shares@ US$2.144.8% of flowCommon StockSEC:0001415889-24-012234:0
4,000 shares@ US$1.743.8% of flowCommon StockSEC:0001415889-24-011251:0
6,853 shares@ US$2.141.1% of flowCommon StockSEC:0001415889-24-011252:0
10,000 shares@ US$2.144.8% of flowCommon StockSEC:0001415889-24-011144:0
7,500 shares@ US$2.142.6% of flowCommon StockSEC:0001415889-24-010773:0
11,882 shares@ US$28.15100.0% of flowCommon StockSEC:0001415889-24-010709:0
3,325 shares@ US$10.612.7% of flowCommon StockSEC:0001415889-24-010137:0
5,300 shares@ US$14.5919.4% of flowCommon StockSEC:0001415889-24-010139:0
12,495 shares@ US$2.144.4% of flowCommon StockSEC:0001415889-24-010136:0
10,000 shares@ US$2.144.8% of flowCommon StockSEC:0001415889-24-010138:0
25 of 142 declarations
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a company listed on the XNAS market, specializing in the development of biopharmaceutical solutions. It focuses on innovation in the life sciences sector.
Recent ranked signals on the same market
Purchases our model currently ranks for the recommendations list.
All recommendations
